Bremelanotide Research & Studies
Part of the full Bremelanotide guide - a synthetic cyclic heptapeptide; alpha-melanocyte-stimulating hormone reference compound, identity-verified with a COA on every vial.
In brief
The research record attached to PT-141 spans two distinct evidence layers, and for a research-use-only reference the relevant layer is the receptor-pharmacology foundation rather than any applied outcome. The provided citations anchor the molecule's characterization as a melanocortin agonist, beginning with the foundational description by Molinoff and colleagues (2003) and extending through pharmacokinetic and clinical-pharmacology reports. Alongside these sources sit five defined research areas that map the in-vitro and preclinical questions the compound is used to investigate: melanocortin receptor pharmacology and radioligand binding, Gs/adenylate-cyclase/cAMP signaling in recombinant GPCR cell models, structure-activity relationships of cyclic lactam-bridged alpha-MSH analogs, NMR and conformational analysis of peptide-receptor interactions, and enzymatic-stability comparisons against linear melanocortins. The sections below describe what those sources and research areas actually examine, restricted to the attributions present in the entry, with the laboratory and receptor-signaling context that defines PT-141's role as a reference ligand.
The detail
A closer look
01
Foundational melanocortin-agonist characterization
The cornerstone citation, Molinoff, Shadiack, Earle, Diamond and Quon (2003) in the Annals of the New York Academy of Sciences, established PT-141 as a melanocortin agonist and is cited in the entry as the source for both the parent-hormone classification (a cyclic heptapeptide analog of alpha-MSH) and the primary in-vitro receptor targets. That work frames the molecule's identity at the receptor-pharmacology level, defining its standing as a melanocortin ligand and grounding the subsequent characterization of its subtype activity across MC4R, MC3R and MC1R. Within a research-use context, this is the reference that situates bremelanotide in the melanocortin literature and underwrites the receptor-target attributions used throughout the spec data. It is the anchor from which the in-vitro binding and functional assays draw their interpretive framework, and the entry leans on it specifically for the agonist classification rather than for any downstream application.
02
Pharmacokinetic and clinical-pharmacology sources
Several of the entry's citations report human pharmacology rather than bench assays, and they are recorded here strictly as bibliographic context for the molecule's broader literature. Diamond, Earle, Rosen, Willett and Molinoff (2004) in the International Journal of Impotence Research evaluated pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141. White, Myers, Jordan and Lucas (2017) in the Journal of Hypertension used ambulatory blood-pressure monitoring to assess the melanocortin receptor agonist. Kingsberg and colleagues (2019) and Safarinejad and Hosseini (2008) report randomized clinical trials. For a research-use-only reference these are catalogued to document the citation trail and the molecule's pharmacokinetic and safety-pharmacology study history; they are not the basis for any laboratory handling guidance, which derives instead from the structural and in-vitro receptor data in the entry.
03
Structure-activity, conformational and stability research areas
Three of the five defined research areas concern the molecule's architecture and durability. Structure-activity relationship work examines how the cyclic lactam bridge together with the D-Phe and Nle substitutions tunes melanocortin receptor engagement, treating bremelanotide as a worked example of constrained alpha-MSH analog design. NMR and conformational analysis investigates how the rigidified backbone presents the His-D-Phe-Arg-Trp pharmacophore to the receptor, linking solution structure to binding behavior. Enzymatic-stability studies compare cyclic, conformationally constrained peptides against linear melanocortins, with the D-Phe substitution and lactam ring cited as features that confer resistance to degradation. These research areas position PT-141 not only as a signaling probe but as a structural model for how cyclization and unnatural residues improve the pharmacological profile of peptide ligands in vitro.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Bremelanotide is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.